JP2017507117A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507117A5
JP2017507117A5 JP2016546462A JP2016546462A JP2017507117A5 JP 2017507117 A5 JP2017507117 A5 JP 2017507117A5 JP 2016546462 A JP2016546462 A JP 2016546462A JP 2016546462 A JP2016546462 A JP 2016546462A JP 2017507117 A5 JP2017507117 A5 JP 2017507117A5
Authority
JP
Japan
Prior art keywords
hpv
antigen
antibody
composition
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016546462A
Other languages
English (en)
Japanese (ja)
Other versions
JP7037884B2 (ja
JP2017507117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/011236 external-priority patent/WO2015106281A1/en
Publication of JP2017507117A publication Critical patent/JP2017507117A/ja
Publication of JP2017507117A5 publication Critical patent/JP2017507117A5/ja
Priority to JP2021197509A priority Critical patent/JP7536737B2/ja
Application granted granted Critical
Publication of JP7037884B2 publication Critical patent/JP7037884B2/ja
Priority to JP2024086175A priority patent/JP2024112966A/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016546462A 2014-01-13 2015-01-13 Hpv及びhpv関連疾患に対する新規のワクチン Expired - Fee Related JP7037884B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021197509A JP7536737B2 (ja) 2014-01-13 2021-12-06 Hpv及びhpv関連疾患に対する新規のワクチン
JP2024086175A JP2024112966A (ja) 2014-01-13 2024-05-28 Hpv及びhpv関連疾患に対する新規のワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926821P 2014-01-13 2014-01-13
US61/926,821 2014-01-13
US201462002718P 2014-05-23 2014-05-23
US62/002,718 2014-05-23
PCT/US2015/011236 WO2015106281A1 (en) 2014-01-13 2015-01-13 Novel vaccines against hpv and hpv-related diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2019207238A Division JP2020036612A (ja) 2014-01-13 2019-11-15 Hpv及びhpv関連疾患に対する新規のワクチン
JP2021197509A Division JP7536737B2 (ja) 2014-01-13 2021-12-06 Hpv及びhpv関連疾患に対する新規のワクチン

Publications (3)

Publication Number Publication Date
JP2017507117A JP2017507117A (ja) 2017-03-16
JP2017507117A5 true JP2017507117A5 (cg-RX-API-DMAC7.html) 2018-02-22
JP7037884B2 JP7037884B2 (ja) 2022-03-17

Family

ID=53524425

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016546462A Expired - Fee Related JP7037884B2 (ja) 2014-01-13 2015-01-13 Hpv及びhpv関連疾患に対する新規のワクチン
JP2019207238A Pending JP2020036612A (ja) 2014-01-13 2019-11-15 Hpv及びhpv関連疾患に対する新規のワクチン
JP2021197509A Active JP7536737B2 (ja) 2014-01-13 2021-12-06 Hpv及びhpv関連疾患に対する新規のワクチン
JP2024086175A Pending JP2024112966A (ja) 2014-01-13 2024-05-28 Hpv及びhpv関連疾患に対する新規のワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019207238A Pending JP2020036612A (ja) 2014-01-13 2019-11-15 Hpv及びhpv関連疾患に対する新規のワクチン
JP2021197509A Active JP7536737B2 (ja) 2014-01-13 2021-12-06 Hpv及びhpv関連疾患に対する新規のワクチン
JP2024086175A Pending JP2024112966A (ja) 2014-01-13 2024-05-28 Hpv及びhpv関連疾患に対する新規のワクチン

Country Status (8)

Country Link
US (5) US10286058B2 (cg-RX-API-DMAC7.html)
EP (2) EP3992210A1 (cg-RX-API-DMAC7.html)
JP (4) JP7037884B2 (cg-RX-API-DMAC7.html)
CN (2) CN120939216A (cg-RX-API-DMAC7.html)
AU (1) AU2015204503B2 (cg-RX-API-DMAC7.html)
CA (1) CA2936833A1 (cg-RX-API-DMAC7.html)
IL (1) IL246759A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015106281A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8961991B2 (en) * 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
CN103415534A (zh) 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
CN120939216A (zh) * 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
HK1256935A1 (zh) * 2016-02-27 2019-10-04 哈普威克斯有限责任公司 使用疫苗治疗癌症或皮肤病变的方法和组合物
NZ750976A (en) 2016-09-19 2023-01-27 I Mab Biopharma Hangzhou Co Ltd Anti-gm-csf antibodies and uses thereof
CA3042703A1 (en) 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of agonist epitopes of the human papillomavirus
CN109021097A (zh) * 2017-06-08 2018-12-18 艾托金生物医药(苏州)有限公司 一种识别hpv18和/或hpv45的单克隆抗体及其应用
CN109384848A (zh) * 2017-08-10 2019-02-26 深圳市雅臣智能生物工程有限公司 抗人乳头瘤病毒和抗cd人源化的双靶向抗体及其组合物、制备方法和应用
EP3762022A4 (en) 2018-03-06 2022-06-15 Precigen, Inc. HUMAN PAPILLOMAVIRUS VACCINES AND USES THEREOF
JP7640466B2 (ja) * 2019-03-27 2025-03-05 アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル Cd40活性化特性を有する組換えタンパク質
CN110054686A (zh) * 2019-04-17 2019-07-26 深圳市雅臣智能生物工程有限公司 抗广谱HPV-L1、E6/E7-IgY及其小分子抗体以及应用
CN111620955B (zh) * 2020-07-01 2022-11-08 北京康爱瑞浩细胞技术有限公司 一种多靶位复合抗原及其应用
EP4267176A1 (en) * 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells
CN117157320A (zh) * 2021-01-29 2023-12-01 国家健康科学研究所 沙眼衣原体抗原性多肽及其用于疫苗目的的用途
KR102514849B1 (ko) * 2021-10-28 2023-03-28 전남대학교산학협력단 수지상 세포를 표적하는 신규한 펩타이드, 및 이를 포함하는 암 치료용 조성물
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
CN116621971B (zh) * 2022-12-16 2025-03-25 生物岛实验室 Hpv18亚型的纳米抗体及其应用
WO2024145863A1 (en) * 2023-01-05 2024-07-11 Virogin Biotech (Shanghai) Ltd. A NOVEL mRNA VACCINE FOR THE TREATMENT AND PREVENTION OF HPV-ASSOCIATED LESIONS AND TUMORS
CN119215159A (zh) * 2024-09-24 2024-12-31 深圳市格茵莱生物科技有限公司 树突状细胞多抗原负载免疫治疗方法

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2403608A (en) 1940-12-19 1946-07-09 Socony Vacuum Oil Co Inc Method of coking oils
US2609508A (en) 1943-04-24 1952-09-02 Bell Telephone Labor Inc Wave generating circuits
US2489708A (en) 1945-01-12 1949-11-29 United Metal Box Co Inc Shelf support combination and cabinet
US2501008A (en) 1948-08-23 1950-03-21 John G Schramm Safety knob
CH482813A (de) 1967-06-16 1969-12-15 Ciba Geigy Flockulationsbeständige Pigmentpräparate und Verfahren zu deren Herstellung
US3613808A (en) 1968-12-18 1971-10-19 Fmc Corp Article-sorting apparatus with transfer-error-reducing arrangement
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE4233152A1 (de) 1992-10-02 1994-04-07 Behringwerke Ag Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE59402827D1 (de) 1993-01-16 1997-06-26 Manfred Dr Schawaller Verfahren zur gewinnung nativer, oligomerer, glykosylierter ektodomänen viraler membranproteine, deren verwendung, insbesondere als impfstoff gegen hiv
ES2146648T3 (es) 1993-03-09 2000-08-16 Genzyme Corp Procedimiento de aislamiento de proteinas de la leche.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP0742721B1 (en) * 1993-09-02 1999-05-06 Trustees of Dartmouth College Methods of prolonged suppression of humoral immunity
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6040137A (en) 1995-04-27 2000-03-21 Tripep Ab Antigen/antibody specification exchanger
US5888773A (en) 1994-08-17 1999-03-30 The United States Of America As Represented By The Department Of Health And Human Services Method of producing single-chain Fv molecules
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
WO1999022008A1 (en) 1997-10-27 1999-05-06 Sumitomo Electric Industries, Ltd. Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
FR2771640B1 (fr) 1997-12-03 2000-02-11 Inst Nat Sante Rech Med Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire et leurs utilisations a des fins therapeutiques
US6541011B2 (en) 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
CN1163602C (zh) 1998-04-07 2004-08-25 科里克萨公司 结核杆菌抗原融合蛋白及其应用
EP1073667A2 (en) 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
WO2000000156A2 (en) 1998-06-26 2000-01-06 Trustees Of Dartmouth College Methods for modulating immunological responses by targeting antigen to apcs in conjuction with anti-cd40 ligands
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001026608A2 (en) 1999-10-14 2001-04-19 Ledbetter Jeffrey A Dna vaccines encoding antigen linked to a domain that binds cd40
GB9926084D0 (en) 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
AU2001259215A1 (en) 2000-04-28 2001-11-12 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
CA2408594A1 (en) 2000-05-08 2001-11-15 Medarex, Inc. Human monoclonal antibodies to dendritic cells
US20030232055A1 (en) 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US6933123B2 (en) 2001-04-05 2005-08-23 Yao Xiong Hu Peptides from the E2, E6, and E7 proteins of human papilloma viruses 16 and 18 for detecting and/or diagnosing cervical and other human papillomavirus associated cancers
ATE374214T1 (de) 2001-04-27 2007-10-15 Kirin Brewery Monoklonaler anti-cd-40-antikörper
JP4025881B2 (ja) 2001-04-27 2007-12-26 キリンファーマ株式会社 抗cd40モノクローナル抗体
WO2003024480A2 (en) 2001-09-14 2003-03-27 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2001298053A1 (en) 2001-09-27 2003-04-14 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
FR2837104B1 (fr) 2002-03-14 2004-08-06 Dev Des Antigenes Combinatoire Utilisation de melange de lipopeptides pour la fabrication de vaccins
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
US20040146948A1 (en) 2002-10-18 2004-07-29 Centenary Institute Of Cancer Medicine And Cell Biology Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
MXPA05005051A (es) 2002-11-12 2006-03-10 Albert B Deisseroth Vacuna de vector adenoviral.
JP2004192125A (ja) 2002-12-09 2004-07-08 Mitsue-Links Co Ltd プロジェクトマネジメントシステム及びそれに用いられるデータ構造、並びに、プロジェクトマネジメント方法
GB0228796D0 (en) 2002-12-11 2003-01-15 Adjuvantix Ltd Valency
CN1747970A (zh) 2003-02-06 2006-03-15 三肽公司 抗原/抗体或配体/受体糖基化的特异性交换剂
EP1599504B1 (en) 2003-02-25 2014-12-03 Vaccibody AS Modified antibody
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
JP4242388B2 (ja) 2003-12-25 2009-03-25 協和発酵キリン株式会社 抗cd40抗体の変異体
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
CA2604909A1 (en) 2005-04-15 2006-10-26 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
JP2007026135A (ja) 2005-07-19 2007-02-01 Shimizu Corp プログラムマネジメントチャート作成支援システム
CA2620667A1 (en) 2005-08-30 2007-04-12 Board Of Regents Of The University Of Nebraska Methods and compositions for vaccination of animals with prrsv antigens with improved immunogenicity
WO2007041861A1 (en) 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
JP2009513680A (ja) 2005-10-28 2009-04-02 セントカー・インコーポレーテツド 抗体の生成におけるb細胞増殖剤の使用
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
CN101421306B (zh) * 2006-04-19 2013-09-18 浦项工科大学校产学协力团 用于治疗和预防子宫颈癌的包含hpv多肽和免疫增强肽的组合物
EP2589654A1 (en) 2006-05-03 2013-05-08 The Regents of the University of Colorado, a body corporate CD40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
CA3163292A1 (en) 2006-09-14 2008-03-20 Veveo, Inc. Methods and systems for dynamically rearranging search results into hierarchically organized concept clusters
JP5687822B2 (ja) 2006-10-12 2015-03-25 中外製薬株式会社 抗ereg抗体を用いる癌の診断および治療
US20080241139A1 (en) 2006-10-31 2008-10-02 Regents Of The University Of Colorado Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
NZ578696A (en) 2007-02-02 2012-01-12 Baylor Res Inst Vaccines based on targeting antigen to dcir expressed an antigen-presenting cells
WO2008097817A2 (en) 2007-02-02 2008-08-14 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
AU2008218184B2 (en) 2007-02-02 2013-01-10 Baylor Research Institute Activation of human antigen-presenting cells through CLEC-6
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑
JP2010519316A (ja) 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート デクチン−1を介したヒト抗原提示細胞の活性化の治療への応用
JP2010518834A (ja) 2007-02-23 2010-06-03 ベイラー リサーチ インスティテュート 樹状細胞のレクチン様酸化ldl受容体−1(lox−1)を介したヒト抗原提示細胞の活性化
CN101743249B (zh) 2007-05-11 2017-08-08 阿尔托生物科学有限公司 融合分子与il‑15变异体
AP2010005284A0 (en) 2007-11-02 2010-06-30 Univ Johns Hopkins Multitype HPV peptide compositions and methods fortreatment or prevention of human papillomavirus i nfection
JP5233505B2 (ja) 2008-03-17 2013-07-10 株式会社リコー 共同作業支援装置、共同作業支援システム、共同作業支援方法、プログラムおよび記録媒体
WO2010009346A2 (en) 2008-07-16 2010-01-21 Baylor Research Institute Hiv vaccine based on targeting maximized gag and nef to dendritic cells
US8961991B2 (en) * 2009-03-10 2015-02-24 Baylor Research Institute Anti-CD40 targeted fusion proteins
CA2735421A1 (en) 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Delivery of a cd40 agonist to a tumor draining lymph node of a subject
CN103415534A (zh) * 2009-03-10 2013-11-27 贝勒研究院 靶向抗原呈递细胞的癌症疫苗
AU2010222942B2 (en) 2009-03-10 2013-01-10 Baylor Research Institute Anti-CD40 antibodies and uses thereof
BRPI1011902A2 (pt) 2009-04-28 2019-09-24 Univ Johns Hopkins composições e métodos para potencialização de respostas imunes antígeno-específicas
EP2470561A1 (en) 2009-08-27 2012-07-04 Novo Nordisk A/S Targeting tissue factor to activated platelets
EP2477655A4 (en) 2009-09-14 2014-02-12 Baylor Res Inst VACCINES TREATED ON LANGERHANS CELLS
WO2011070124A2 (en) 2009-12-10 2011-06-16 Fruitful Innovations B.V. Improved catalytic process for reacting carbon dioxide with hydrogen
GB201003293D0 (en) * 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
RU2012152828A (ru) 2010-05-07 2014-06-20 Бейлор Рисёч Инститьют Опосредованное иммунорецепторами дендритных клеток (dcir) перекрестное примирование cd8+ т клеток человека
WO2011158019A1 (en) * 2010-06-16 2011-12-22 Adjuvantix Limited Polypeptide vaccine
RU2013110889A (ru) 2010-08-13 2014-09-20 Бейлор Рисёч Инститьют Новые вакцинные адъюванты на основе адъювантов-антител, нацеливающих непосредственно на антигенпрезентирующие клетки
JP5022520B2 (ja) 2010-09-01 2012-09-12 有限会社栄ライト工業所 計画作成支援プログラム及び計画作成支援システム
WO2012122396A1 (en) 2011-03-08 2012-09-13 Baylor Research Institute Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
EP2688591A4 (en) 2011-03-22 2014-10-01 Baylor Res Inst TARGETING DENDRITIC CELLS FOR A TUBERCULOSIS VACCINE
EP2688592A4 (en) * 2011-03-25 2015-07-22 Baylor Res Inst Compositions and methods for immunization against the hepatitis C virus
AR088428A1 (es) 2011-08-25 2014-06-11 Baylor Res Inst Ensayo multiplexado basado en esferas autoensambladas para anticuerpos especificos de antigenos
US9901635B2 (en) 2011-12-21 2018-02-27 Vaccibody As Vaccines against HPV
CN120939216A (zh) * 2014-01-13 2025-11-14 贝勒研究院 抗hpv和hpv相关的疾病的新疫苗
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Similar Documents

Publication Publication Date Title
JP2017507117A5 (cg-RX-API-DMAC7.html)
Tornesello et al. Virus-like particles as preventive and therapeutic cancer vaccines
Jagu et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines
Dochez et al. HPV vaccines to prevent cervical cancer and genital warts: an update
Khallouf et al. Therapeutic vaccine strategies against human papillomavirus
Huber et al. RG1-VLP and other L2-based, broad-spectrum HPV vaccine candidates
Tran et al. Control of HPV infection and related cancer through vaccination
CN107163107B (zh) 用于治疗或预防人乳头瘤病毒感染的多型hpv肽的组合物和方法
Lee et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects
Jagu et al. Optimization of multimeric human papillomavirus L2 vaccines
JP2013532971A5 (cg-RX-API-DMAC7.html)
Komatsu et al. Optimization of human papillomavirus (HPV) type 16 E7-expressing lactobacillus-based vaccine for induction of mucosal E7-specific IFNγ-producing cells
Kawana et al. Human papillomavirus vaccines: current issues & future
JP2015529678A5 (cg-RX-API-DMAC7.html)
Olczak et al. Progress in L2-based prophylactic vaccine development for protection against diverse human papillomavirus genotypes and associated diseases
Tyler et al. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing
EA201071366A1 (ru) Комбинированная вакцина против кори и вируса папилломы человека
JP2019525735A (ja) Hpv l2ペプチドの免疫原性の改善
Jiang et al. Progress and prospects for L2-based human papillomavirus vaccines
Kalnin et al. Incorporation of RG1 epitope concatemers into a self-adjuvanting Flagellin-L2 vaccine broaden durable protection against cutaneous challenge with diverse human papillomavirus genotypes
Ribeiro-Müller et al. Prophylactic papillomavirus vaccines
Mishra et al. HPV vaccine: One, two, or three doses for cervical cancer prevention?
Zhao et al. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine
Meyer et al. Cell‐mediated immune response: a clinical review of the therapeutic potential of human papillomavirus vaccination
Sharma et al. A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer